ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Harvard’s Richmond Said To Be The Choice As Asst. secretary; Lee Clark Convalescing

May 6, 1977

Obituary: Michale Keeling, of M.D. Anderson.

January 2, 2004

SWOG Seeks NSCLC Patients For Study Of Gender Differences In Lung Cancer

October 28, 2005

Ford To Resubmit Budget Slash Of $125 Million For NCI

January 3, 1975

Roswell Park Wins Grants For Young Investigators.

January 11, 2002

Yarbro-Chabner Debate Continues

April 29, 1983